生物标志物发现
疾病
临床试验
生物标志物
医学
药物开发
生物信息学
转化研究
计算生物学
药物发现
临床实习
重症监护医学
数据科学
计算机科学
蛋白质组学
病理
药品
生物
药理学
家庭医学
生物化学
基因
作者
Stephen M. Hewitt,James W. Dear,Robert A. Star
出处
期刊:Journal of The American Society of Nephrology
日期:2004-07-01
卷期号:15 (7): 1677-1689
被引量:285
标识
DOI:10.1097/01.asn.0000129114.92265.32
摘要
ABSTRACT. Animal models and human studies have been useful in dissecting the molecular mechanisms of renal disease and finding new disease targets; however, translation of these findings to new clinical therapeutics remains challenging. Difficulties with detecting early disease, measuring drug effectiveness, and the daunting cost of clinical trials hampers the development of new therapeutics for renal diseases. Many existing laboratory tests were discovered because of inspired recognition that a particular protein might prove useful in clinical practice. New unbiased genomic and proteomic techniques identify many constituents present in biologic samples and thus may greatly accelerate biomarker research. This review focuses on the steps needed to develop new biomarkers that are useful in laboratory and clinical investigations, with particular focus on new proteomic screening technologies. New biomarkers will speed the laboratory and clinical development of new treatments for renal diseases through mechanistic insights, diagnoses that are more refined, early detection, and enhanced proof of concept testing.
科研通智能强力驱动
Strongly Powered by AbleSci AI